The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world tolerability of front-line brigatinib in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) with and without brain metastases in the United States.
 
Edmund W. Tai
Honoraria - Syneos Health
Speakers' Bureau - Syneos Health; Takeda/Millennium
 
Huamao Mark Lin
Employment - Takeda/Millennium
Stock and Other Ownership Interests - Takeda/Millennium
 
Yanyu Wu
Employment - Takeda/Millennium
Stock and Other Ownership Interests - Takeda/Millennium
 
Yin Wan
Employment - Takeda/Millennium
Stock and Other Ownership Interests - Takeda/Millennium
 
Magdaliz Gorritz
Research Funding - Amgen (Inst); AstraZeneca (Inst); Lilly (Inst); Novartis (Inst); Otsuka (Inst); Takeda/Millennium (Inst); Travere Therapeutics (Inst)
 
Xiaoyu Zhou
Research Funding - Takeda/Millennium (Inst)
 
Chi-Chang Chen
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Regeneron (Inst); Takeda/Millennium (Inst)
 
Yuanbin Chen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Guardant Health; Jazz Pharmaceuticals; Merck; Pfizer; Takeda
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; Genentech; Ipsen; Merck; Merck Serono
Expert Testimony - AstraZeneca; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Ipsen